United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 29.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 675 shares of the biotechnology company’s stock after buying an additional 155 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in United Therapeutics were worth $238,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in UTHR. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics in the fourth quarter worth approximately $25,000. Brooklyn Investment Group acquired a new position in United Therapeutics in the third quarter worth approximately $33,000. MassMutual Private Wealth & Trust FSB grew its position in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after buying an additional 58 shares during the last quarter. Jones Financial Companies Lllp grew its position in United Therapeutics by 678.9% in the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after buying an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in United Therapeutics in the fourth quarter worth approximately $131,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.6 %

Shares of NASDAQ:UTHR opened at $307.24 on Friday. The firm has a fifty day moving average of $349.77 and a two-hundred day moving average of $358.48. The firm has a market capitalization of $13.80 billion, a P/E ratio of 13.49, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 12-month low of $221.53 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the business posted $4.36 EPS. Equities research analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the sale, the director now owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the sale, the director now directly owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 116,464 shares of company stock valued at $42,396,244 in the last quarter. Company insiders own 11.90% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on UTHR. HC Wainwright reiterated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.